scholarly journals CA-125 Antigen Concentration in Healthy Women of Different Age Groups and at Different Stages of the Ovary Malignant Neoplastic Transformation Development

2016 ◽  
Vol 2016 (2) ◽  
pp. 53-58
Author(s):  
O. YAKUBETS ◽  
◽  
D. VOROBETS ◽  
L. ODNORIH ◽  
Z. VOROBETS ◽  
...  
Keyword(s):  
Age Groups ◽  
Neoplastic Transformation ◽  
Ca 125 ◽  
Antigen Concentration ◽  
Healthy Women ◽  
Ca 125 Antigen

scholarly journals Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women

1999 ◽  
Vol 15 (4) ◽  
pp. 259-267 ◽  
Author(s):  
Ayşe Binnur Erbağci ◽  
Necat Yilmaz ◽  
Irfan Kutlar
Keyword(s):  
Menstrual Cycle ◽  
Tumor Markers ◽  
Normal Function ◽  
Ca 125 ◽  
Diagnostic Efficiency ◽  
Healthy Women ◽  
Healthy Female ◽  
Serum Cea ◽  
Cycle Dependent

Information on menstrual cycle dependent variation of tumor markers in healthy women is a subject of diagnostic efficiency and has an impact in elucidating the normal function of these markers. In this study midfollicular and midluteal concentrations of serum CEA, AFP, CA 19-9, CA 125, CA 15-3 and their relations with LH, FSH, prolactin, estradiol and progesterone were evaluated during ovulatory cycles in a group of 23 healthy female individuals. Samples were collected on the 7th and 21st day of the same menstrual cycle. Tumor marker and hormone concentrations were determined with chemiluminescence or electrochemiluminescence EIA methods. A significant phase-dependent difference was observed for CA 15-3, midluteal concentrations (mean ± SEM; 26.33 ± 1.56 U/ml) higher than the midfollicular (mean ± SEM; 19.27 ± 1.49 U/ml) concentrations (p < 0.001). But an obvious difference for other tumor markers investigated did not exist. Significant correlations of follicular and luteal CA 125 levels with body mass index of the subjects were observed (r:0.52, p < 0.05 and r:0.57, p < 0.005, respectively).CA 15-3 antigen is a product of the MUC-1 gene which is expressed in abundance by endometrial epithelial cells in the secretory phase of the menstrual cycle which may be the potential source of variability. The association of CA 125 levels with obesity suggests a possible role of adipose tissue in CA 125 metabolism. In conclusion our data suggest that in healthy women serum CA 15-3 levels are significantly elevated in the midluteal phase of the menstrual cycle compared to midfollicular phase. Therefore, consideration of menstrual cycle dependent variability for CA 15-3 appears indicated in interpretation of individual results.

scholarly journals Comparison of seven immunoassays for the quantification of CA 125 antigen in serum

1998 ◽  
Vol 44 (7) ◽  
pp. 1417-1422 ◽  
Author(s):  
Elvira M Davelaar ◽  
Gerard J van Kamp ◽  
Rob A Verstraeten ◽  
Peter Kenemans
Keyword(s):  
Ovarian Cancer ◽  
Clinical Performance ◽  
Correlation Coefficients ◽  
Roc Curves ◽  
Ca 125 ◽  
Serum Samples ◽  
Pelvic Tumors ◽  
Value Range ◽  
Patient Groups ◽  
Ca 125 Antigen

Abstract Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were determined in 289 serum samples obtained from women with benign pelvic tumors (samples from 98 patients) and patients with various cancers (samples from 111 patients). In the range of 0–1000 kilounits/L, all assays tested were linearly correlated, with correlation coefficients ranging from 0.89 to 0.99. In relation to the original Centocor CA 125 assay, there was an overall tendency to measure higher absolute values in the lower CA 125 value range. This was not seen in relation to the Centocor CA 125 II assay. ROC curves (benign vs pretreatment ovarian cancer patients) were nearly identical for all assays, and the areas under the ROC curves were not markedly different. We conclude that the CA 125 assays tested are strongly related to each other and are clinically reliable for the quantification of serum CA 125 and that none of the assays offers higher diagnostic accuracy or better discrimination between patient groups, especially not in the lower ranges.

Clinical Evaluation of a New Two-Site Assay for CA125 Antigen

1991 ◽  
Vol 6 (2) ◽  
pp. 129-135 ◽  
Author(s):  
V. Capstick ◽  
G.D. Maclean ◽  
M.R. Suresh ◽  
D. Bodnar ◽  
S. Lloyd ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Response To Therapy ◽  
Ca 125 ◽  
Unknown Primary ◽  
Ovarian Adenocarcinoma ◽  
Healthy Donors ◽  
Response To Chemotherapy ◽  
The Mean ◽  
Ca 125 Antigen

As appropriate surgery and chemotherapy can improve both quality of life and survival of patients with ovarian adenocarcinoma, there has been a pressing need for “serodiagnostic” assays to enable close patient monitoring. CA 125 antigen has previously been described as a useful tumor marker of ovarian cancer. This is the first clinical evaluation of a radioimmunoassay using two new monoclonal antibodies, B27.1 and B43.13, that react with separate sites on the glycoprotein marker CA 125. Using the new assay, the majority of patients with clinically or radiologically detectable disease had serum CA 125 antigen levels well above the upper limit seen with random apparently healthy donors, while only three patients who were believed free of disease had elevated levels. Disease progression was associated with increasing values of serum CA 125 antigen, while response to therapy was associated with a steady decline in serum CA 125 antigen levels. Seven patients had steadily rising serum CA 125 antigen levels after initially having normal levels. The mean lead time between rise above normal and clinical or radiological evidence of relapse was 5 months (range 2 to 12 months). The merits of further surgical intervention are illustrated by the serial values of two patients followed after chemotherapy. The assay appears to have value in monitoring response to therapy and in detecting disease relapse at a time when appropriate therapeutic intervention is still possible or likely to be beneficial. Furthermore, monitoring CA 125 antigen was shown to be of benefit in assessing response to chemotherapy in a few patients with metastatic adenocarcinoma of unknown primary, and may be useful in this group of patients in determining those likely to benefit from aggressive chemotherapy.

scholarly journals Development of a Multimarker Assay for Early Detection of Ovarian Cancer

2010 ◽  
Vol 28 (13) ◽  
pp. 2159-2166 ◽  
Author(s):  
Zoya Yurkovetsky ◽  
Steven Skates ◽  
Aleksey Lomakin ◽  
Brian Nolen ◽  
Trenton Pulsipher ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Late Stage ◽  
Early Stage ◽  
Screening Strategy ◽  
Ca 125 ◽  
Great Promise ◽  
Biomarker Panel ◽  
Healthy Women ◽  
Early Stage Ovarian Cancer

PurposeEarly detection of ovarian cancer has great promise to improve clinical outcome.Patients and MethodsNinety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays. A Metropolis algorithm with Monte Carlo simulation (MMC) was used for analysis of the data.ResultsA training set, including sera from 139 patients with early-stage ovarian cancer, 149 patients with late-stage ovarian cancer, and 1,102 healthy women, was analyzed with MMC algorithm and cross validation to identify an optimal biomarker panel discriminating early-stage cancer from healthy controls. The four-biomarker panel providing the highest diagnostic power of 86% sensitivity (SN) for early-stage and 93% SN for late-stage ovarian cancer at 98% specificity (SP) was comprised of CA-125, HE4, CEA, and VCAM-1. This model was applied to an independent blinded validation set consisting of sera from 44 patients with early-stage ovarian cancer, 124 patients with late-stage ovarian cancer, and 929 healthy women, providing unbiased estimates of 86% SN for stage I and II and 95% SN for stage III and IV disease at 98% SP. This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.ConclusionA panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.

scholarly journals Age-related changes in muscle thickness and echo intensity of trunk muscles in healthy women: comparison of 20–60s age groups

2020 ◽  
Vol 120 (8) ◽  
pp. 1805-1814 ◽  
Author(s):  
Megumi Ota ◽  
Tome Ikezoe ◽  
Takehiro Kato ◽  
Hiroshige Tateuchi ◽  
Noriaki Ichihashi
Keyword(s):  
Age Groups ◽  
Muscle Thickness ◽  
Trunk Muscles ◽  
Echo Intensity ◽  
Healthy Women ◽  
Age Related ◽  
Age Related Changes

Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors

Cancer ◽  
1987 ◽  
Vol 60 (10) ◽  
pp. 2437-2442 ◽  
Author(s):  
Gert Jan Fleuren ◽  
Marius Nap ◽  
Jan G. Aalders ◽  
J. Baptist Trimbos ◽  
Henk W. A. de Bruijn
Keyword(s):  
Ovarian Tumors ◽  
Ca 125 ◽  
Ca 125 Antigen

The Prevalence of Anemia among Healthy Women in Japan.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3755-3755
Author(s):  
Eiji Kusumi ◽  
Masahiro Kami ◽  
Midori Shoji ◽  
Shigeyuki Endou ◽  
Yukiko Kishi ◽  
...  
Keyword(s):  
Age Groups ◽  
Japanese Woman ◽  
Microcytic Anemia ◽  
Deficiency Anemia ◽  
Iron Intake ◽  
Nutrition Survey ◽  
Healthy Women ◽  
The Us ◽  
Working Age ◽  
Prevalence Of Anemia

Abstract Introduction Anemia is common among young women. National Health and Nutrition Examination Survey (NHENES) revealed that the insufficient iron intake is one of the leading causes of anemia in the US. In Europe and the US, iron fortification of flour increased oral iron intake and decreased anemia prevalence from 30% to 10%. The National Nutrition Survey in Japan by the Ministry of Health, Labour and Welfare in 2002 revealed the estimated anemia prevalence of 19 %. Currently, no nationwide preventive policy aims at iron deficiency anemia. However, the prevalence of 19% was estimated based on 3,156 persons in the Survey. Objective The endpoint of this study was to estimate anemia prevalence among healthy Japanese woman based on a larger sample size. Method We collected data from consecutive check-up examination records of apparently healthy women in different age groups in Toranomon Hopital (between January 2002 and March 2005, n = 8,264) and Yuai Memorial Hospital (between February 1998 and February 2005, n = 5,153). We defined hemoglobin lower than 12 g/dL as anemia, hemoglobin lower than 10 g/dL as severe anemia, and mean corpuscular volume lower than 80 fl as microcytic anemia. Results The median age was 47 years (range, 11–87 years). Of the 13,147 persons, anemia was identified in 2,331 (17.3 %), and severe and microcytic anemia in 438 (3.3 %) and 700 (5.2 %), respectively. The prevalence of anemia and median hemoglobin values by age groups are shown in Figure. The median hemoglobin values tended to be lower in women of the age groups with high anemia prevalence. Conclusion The prevalence of anemia among women of child-bearing age and of working age is high in Japan. As the Japanese population is rapidly decreasing and aging, some action needs to be considered to improve quality of life during pregnancy and working efficiency. Figure Figure.

Specificity and Affinity of 26 Monoclonal Antibodies against the CA 125 Antigen: First Report from the ISOBM TD-1 Workshop

Tumor Biology ◽  
1996 ◽  
Vol 17 (4) ◽  
pp. 196-219 ◽  
Author(s):  
K. Nustad ◽  
R.C. Bast, Jr. ◽  
T.J. O&rsquo;Brien ◽  
O. Nilsson ◽  
P. Seguin ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Ca 125 ◽  
First Report ◽  
Ca 125 Antigen

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

2006 ◽  
Vol 103 (1) ◽  
pp. 195-198 ◽  
Author(s):  
Maurie Markman ◽  
Massimo Federico ◽  
P.Y. Liu ◽  
Edward Hannigan ◽  
David Alberts
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Advanced Ovarian Cancer ◽  
Ca 125 ◽  
Antigen Level ◽  
Ca 125 Antigen
Sign in / Sign up

Export Citation Format

Share Document